The case for loosening is getting stronger
As inflation eases, central banks now find themselves at the most difficult point in the policymaking cycle
As inflation eases, central banks now find themselves at the most difficult point in the policymaking cycle As inflation eases, central banks now find themselves at the most difficult point in the policymaking cycle Moneycontrol Latest News Read More
As inflation eases, central banks now find themselves at the most difficult point in the policymaking cycle
NMDC trades in red even as Q2 net profit jumps 15%; brokerages remain upbeat
The NMDC stock has given a return of 64.22 percent over the last six months. The benchmark Nifty50 index has given a return of 5.68 percent over the same duration.
The NMDC stock has given a return of 64.22 percent over the last six months. The benchmark Nifty50 index has given a return of 5.68 percent over the same duration. The NMDC stock has given a return of 64.22 percent over the last six months. The benchmark Nifty50 index has given a return of 5.68 percent over the same duration. Moneycontrol Latest News Read More
The NMDC stock has given a return of 64.22 percent over the last six months. The benchmark Nifty50 index has given a return of 5.68 percent over the same duration.
NMDC trades in red even as Q2 net profit jumps 15%; brokerages remain upbeat
The NMDC stock has given a return of 64.22 percent over the last six months. The benchmark Nifty50 index has given a return of 5.68 percent over the same duration.
The NMDC stock has given a return of 64.22 percent over the last six months. The benchmark Nifty50 index has given a return of 5.68 percent over the same duration. The NMDC stock has given a return of 64.22 percent over the last six months. The benchmark Nifty50 index has given a return of 5.68 percent over the same duration. Moneycontrol Latest News Read More
The NMDC stock has given a return of 64.22 percent over the last six months. The benchmark Nifty50 index has given a return of 5.68 percent over the same duration.
Renault#39;s EV unit Ampere targets 10 billion euros revenues in 2025
The group set out financial targets for the unit, including an expected break-even in 2025 and an operating margin of at least 10% from 2030, ahead of an investor day meant to drum up support for the initial public offering slated for spring 2024.
The group set out financial targets for the unit, including an expected break-even in 2025 and an operating margin of at least 10% from 2030, ahead of an investor day meant to drum up support for the initial public offering slated for spring 2024. The group set out financial targets for the unit, including an expected break-even in 2025 and an operating margin of at least 10% from 2030, ahead of an investor day meant to drum up support for the initial public offering slated for spring 2024. Moneycontrol Latest News Read More
The group set out financial targets for the unit, including an expected break-even in 2025 and an operating margin of at least 10% from 2030, ahead of an investor day meant to drum up support for the initial public offering slated for spring 2024.
FO Manual: Exuberance in Indian equity indices; analysts maintain moderately bullish stance on Nifty
The index has successfully held above the pivotal 19400 zone, a crucial factor in maintaining the current bias and sentiment. As per analysts, once a decisive move beyond the 19650 zone is established, a clear directional shift with conviction is anticipated
The index has successfully held above the pivotal 19400 zone, a crucial factor in maintaining the current bias and sentiment. As per analysts, once a decisive move beyond the 19650 zone is established, a clear directional shift with conviction is anticipated The index has successfully held above the pivotal 19400 zone, a crucial factor in maintaining the current bias and sentiment. As per analysts, once a decisive move beyond the 19650 zone is established, a clear directional shift with conviction is anticipated Moneycontrol Latest News Read More
The index has successfully held above the pivotal 19400 zone, a crucial factor in maintaining the current bias and sentiment. As per analysts, once a decisive move beyond the 19650 zone is established, a clear directional shift with conviction is anticipated
Gland Pharma gets tentative USFDA nod for blood pressure medication
Gland Pharma believes that it is the only company with first to file for this product and may be eligible for 180 days of generic drug exclusivity.
Gland Pharma believes that it is the only company with first to file for this product and may be eligible for 180 days of generic drug exclusivity. Gland Pharma believes that it is the only company with first to file for this product and may be eligible for 180 days of generic drug exclusivity. Moneycontrol Latest News Read More
Gland Pharma believes that it is the only company with first to file for this product and may be eligible for 180 days of generic drug exclusivity.
हिन्दी 
English